Pharmaceutical Compositions and Methods Utilizing a D-Amino Acid

• US 20090176715A1
• Filed: 01/08/2009
• Published: 07/09/2009
• Est. Priority Date: 01/09/2008
• Status: Abandoned Application

• Current Assignee: Amino Acid Solutions, Inc.
• Original Assignee: Amino Acid Solutions, Inc.
• Inventors: Javitt, Daniel
• Application Number:
  US12/350,901
• Publication Number:
  US 20090176715A1
• Time in Patent Office: Days
• US Class Current: 514/1.100
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/133 having hydroxy groups, e.g. sphingosine
• CPC Class Codes: A61K 31/145 having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2) isothiourea A61K31/155
• CPC Class Codes: A61K 31/198 Alpha-amino acids, e.g. alanine or edetic acid [EDTA] betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00
• CPC Class Codes: A61K 31/355 Tocopherols, e.g. vitamin E
• CPC Class Codes: A61K 31/375 Ascorbic acid, i.e. vitamin C; Salts thereof
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/14 for treating abnormal movements, e.g. chorea, dyskinesia
• CPC Class Codes: A61P 25/16 Anti-Parkinson drugs
• CPC Class Codes: A61P 25/18 Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
• CPC Class Codes: A61P 25/24 Antidepressants
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

The present invention provides a pharmaceutical composition for oral administration comprising a D-amino acid combined with an antioxidant selected from the group consisting of vitamin E, vitamin C, a glutathione or a precursor thereof.

Claims

1. A pharmaceutical composition for oral administration comprising a D-amino acid combined with an antioxidant selected from the group consisting of vitamin E, vitamin C, a glutathione or a precursor thereof.

2. A pharmaceutical composition according to claim 1 in which the D-amino acid is selected from the group consisting of D-serine, D-alanine, D-cysteine, D-homocysteine, or D-threonine

3. A pharmaceutical composition according to claim 1 wherein the antioxidant is glutathione or a precursor thereof.

4. A pharmaceutical composition according to claim 3 wherein the glutathione precursor is selected from the group consisting of L-cysteine or N-acetyl-L-cysteine and racemic versions or combinations thereof

5. A pharmaceutical composition according to claim 1 wherein the antioxidant is vitamin E.

6. A pharmaceutical composition according to claim 1 wherein the antioxidant is vitamin C.

7. A pharmaceutical composition according to of claim 1 where the D-amino acid and antioxidant are present in molar ratios of between 1:

10 and 10;

1.

8. A method for treating a neuropsychiatric disorder characterized by attenuated NMDA neurotransmission comprising administering the pharmaceutical composition of claim 1

9. The method of claim 8, wherein the neuropsychiatric disorder is schizophrenia, schizophreniform disorder, psychosis NOS, or prodromal schizophrenia

10. The method of claim 8, wherein the neuropsychiatric disorder is Alzheimer'"'"'s disease.

11. The method of claim 8, wherein the neuropsychiatric disorder is autism.

12. The method of claim 8, wherein the neuropsychiatric disorder is depression.

13. The method of claim 8 wherein the neuropsychiatric disorder is benign forgetfulness.

14. The method of claim 8, wherein the neuropsychiatric disorder is a childhood learning disorder.

15. The method of claim 8, wherein the neuropsychiatric disorder is attention deficit disorder.

16. The method of claim 8, wherein the neuropsychiatric disorder is close head injury.

17. The method of claim 8, wherein the neuropsychiatric disorder is a movement disorder.

18. The method of claim 17 where the movement disorder is Parkinsons disease, Huntingtons chorea, Wilsons disease, Tourette'"'"'s disease, tic disorders, or obsessive-compulsive disorder.

19. A method for treating a neuropsychiatric disorder characterized by attenuated NMDA neurotransmission in a patient, the method comprising administering to a patient diagnosed as suffering from the neuropsychiatric disorder an oral pharmaceutical composition comprising a therapeutically effective amount of a D-amino acid combined with a an anti-oxidant selected from the group consisting of vitamin E, vitamin C, a glutathione or a precursor thereof